-
Medroxyprogesterone Acetate: Assay Design Guide
2026-09-04
Medroxyprogesterone acetate (MPA) is a versatile steroidal probe for separating progesterone receptor, glucocorticoid receptor, and tissue-specific signaling. This assay-design guide connects MPA research with vitamin D/VDR-driven decidualization while emphasizing controls, interpretation, and practical handling.
-
Z-LEHD-FMK: Practical Caspase-9 Inhibition
2026-09-03
Z-LEHD-FMK provides a targeted way to test whether mitochondria-mediated apoptosis depends on caspase-9 rather than relying on endpoint viability alone. This workflow-focused guide connects infection biology, cancer research, and neuroprotection assays while emphasizing controls, solvent handling, and pathway-specific interpretation.
-
Protease Inhibitor Cocktail: EDTA-Free Workflow
2026-09-03
Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO) helps limit proteolytic loss during cell lysis, protein extraction, and downstream protein assays. It is appropriate for cation-sensitive workflows, but it should not replace rapid sample handling, cold processing, vehicle controls, or assay-specific compatibility testing.
-
1-Phenyl-2-Pentanol and Hepatic Fibrosis
2026-09-02
The reference study identifies 1-Phenyl-2-Pentanol from Moringa oleifera leaves and shows that it suppresses profibrotic responses in TGF-β1-stimulated human hepatic stellate cells. Its combination of cell-based marker analysis, proteomics, and molecular docking connects reduced extracellular-matrix signaling with possible effects on TGF-β1 and Wnt/β-catenin pathways, while still requiring validation in more complex models.
-
ISRIB (trans-isomer): PERK Inhibitor Workflows
2026-09-02
ISRIB (trans-isomer) gives researchers a practical way to test how ISR-driven translation control shapes ER stress, apoptosis, and fibrotic signaling. This workflow-focused guide connects eIF2B-centered ISR modulation with the ATF4 enhancer program identified in hepatic stellate cells.
-
CDK9 inhibitor (A3294): Protocol Guide
2026-09-01
CDK9 inhibitor (A3294) is a selective serine/threonine kinase inhibitor for examining CDK9-dependent transcription elongation and HIV-1 propagation mechanisms. It is appropriate for controlled biochemical and cell-based research, but not for broad-spectrum CDK inhibition, clinical inference, or protocols requiring long-term storage of working solutions.
-
DAPI (hydrochloride) for Pancreatic Organoid QC
2026-09-01
DAPI (hydrochloride) converts pancreatic ductal organoid morphology into measurable nuclear, DNA-content, and cell-cycle readouts. This guide pairs a practical staining workflow with the small-molecule organoid strategy reported in the reference study, while addressing live-cell permeability, solubility, multiplexing, and flow-cytometry pitfalls.
-
Dovitinib (TKI-258, CHIR-258) Assay Guide
2026-08-31
This scenario-based guide explains how Dovitinib (TKI-258, CHIR-258), SKU A2168, can support reproducible viability, signaling, and apoptosis experiments in RTK-driven cancer models. It connects formulation choices and orthogonal readouts with current evidence on circulating cancer-associated macrophage-like cells while clearly separating established findings from practical workflow recommendations.
-
(+)-Bicuculline Protocol and QC Guide
2026-08-30
(+)-Bicuculline is a GABAA receptor antagonist used to investigate inhibitory synaptic transmission, GABAergic signaling, and related neuronal pathway responses. This guide covers preparation, storage, assay controls, and evidence boundaries; the compound is for controlled scientific research only and not for diagnostic, therapeutic, or medical use.
-
Everolimus (RAD001): From mTOR Signal to Translation
2026-08-29
Everolimus (RAD001) is more than a pathway inhibitor: it is a translational tool for separating cancer cell proliferation inhibition from cell killing. This article connects mTOR mechanism, assay design, exposure-aware interpretation, and in vivo strategy for researchers advancing renal cell carcinoma research and ovarian cancer models.
-
CBD, Orofacial Inflammatory Pain, and Pain-Related Affect
2026-08-29
A 2026 Brain Research Bulletin study shows that cannabidiol reduces both nociceptive and affective abnormalities in mouse models of inflammatory pain. Its main contribution is a multi-level mechanistic framework linking peripheral CB2-associated anti-inflammatory effects, central CB1-related endocannabinoid signaling, and serotonin dynamics in the central amygdala.
-
TRIM26, NDP52, and MAVS in PRV Immune Evasion
2026-08-28
The reference study identifies TRIM26 as a proviral factor in pseudorabies virus infection and defines an NDP52-dependent autophagic route for MAVS degradation. Its findings connect TRIM-family regulation, selective autophagy, and RIG-I–MAVS signaling, providing a mechanistic framework for understanding how PRV weakens type I interferon defenses.
-
SHC-1 Inhibition and CFTR Surface Trafficking
2026-08-28
The reference study shows that MAPK/SHC-1-dependent internalization of CFTR is detectable across airway and intestinal epithelial models, but that pharmacological SHC-1 inhibition increases surface CFTR only in CFBE cells. Its main contribution is to separate a conserved trafficking mechanism from a cell-specific response, highlighting why surface abundance, signaling activity, and channel function must be measured together.
-
FXR Phase Separation Organizes Coronavirus Replication
2026-08-27
Li et al. show that fragile X–related proteins organize β-coronavirus double-membrane vesicles through liquid–liquid phase separation, linking condensate biology to replication-organelle architecture. The work identifies FXR-dependent DMV clustering as a host process that supports efficient viral translation and SARS-CoV-2 replication, while also suggesting imaging strategies for studying these structures.
-
Artemisinin, Nrf2, and Ferroptosis in Diabetic Cognition
2026-08-27
Wang et al. show that artemisinin improves cognitive deficits in STZ-induced type 2 diabetes mellitus mice by activating hippocampal Nrf2 and suppressing neuronal ferroptosis. The study combines behavioral testing, redox and iron measurements, protein analysis, histology, and pharmacological intervention to support a mechanistic link between Nrf2 activity and diabetic cognitive injury.